Indian Drug Prices Discussed In Parliament

11 August 1997

Drug prices in India increased 1.7% during the period April 1996 toMarch 1997, compared to 5.9% for the prices of all commodities, Chemical and Fertilizers Minister M Arunachalam told the Lower House of Parliament earlier this month.

Mr Arunachalam said the analysis of causes of higher medicines prices, both those under and outside price controls, revealed the increase in the prices of several other inputs as prime factors. Among these are bulk drugs, excipients, packaging, exchange rate fluctuations for imported items, changes in excise duty and a hike in Maximum Allowable Post-manufacturing Expenses.

No Plans To Cut Prices He also informed the House that there was no pending proposal with the government to slash the prices of bulk drugs at present. Currently, bulk drugs are being sold at much higher prices than the notified rates. Notified prices are the maximum selling prices of products, and Mr Arunachalam said that these could be reduced by the government whenever it comes to its notice that the input costs had substantially decreased.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight